This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ISR Overzicht aandelen
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
ISR Immune System Regulation Holding AB (publ) Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | SEK 1.40 |
| 52 Week Hoogtepunt | SEK 8.60 |
| 52 Week Laag | SEK 1.19 |
| Bèta | 0.45 |
| 11 maand verandering | 0% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -74.45% |
| 33 jaar verandering | -50.70% |
| 5 jaar verandering | -86.21% |
| Verandering sinds IPO | -86.98% |
Recent nieuws en updates
Recent updates
We're Not Very Worried About ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Rate
Aug 11
A Look At The Fair Value Of ISR Immune System Regulation Holding AB (publ) (STO:ISR)
Jul 02Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Mar 08Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Nov 18Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Jul 27Here's Why We're Watching ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Situation
Mar 26We Think ISR Immune System Regulation Holding (STO:ISR) Can Afford To Drive Business Growth
Dec 11
Rendement voor aandeelhouders
| ISR | SE Biotechs | SE Markt | |
|---|---|---|---|
| 7D | 0% | 3.5% | -0.2% |
| 1Y | -74.5% | 36.9% | 28.4% |
Rendement versus industrie: ISR underperformed the Swedish Biotechs industry which returned 4% over the past year.
Rendement versus markt: ISR underperformed the Swedish Market which returned -6.8% over the past year.
Prijsvolatiliteit
| ISR volatility | |
|---|---|
| ISR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stabiele aandelenkoers: ISR's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: Insufficient data to determine ISR's volatility change over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 5 | Ola Winqvist | israb.se |
ISR Immune System Regulation Holding AB (publ) Samenvatting
| ISR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | SEK 96.61m |
| Inkomsten(TTM) | -SEK 213.05m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-0.5x
Koers/WinstverhoudingIs ISR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ISR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | SEK 0 |
| Kosten van inkomsten | SEK 0 |
| Brutowinst | SEK 0 |
| Overige uitgaven | SEK 213.05m |
| Inkomsten | -SEK 213.05m |
Laatst gerapporteerde inkomsten
Dec 31, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.09 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | -0.6% |
Hoe presteerde ISR op de lange termijn?
Bekijk historische prestaties en vergelijking